Tenaya Therapeutics ends lease on decommissioned manufacturing site
The company will exit its former gene therapy manufacturing facility in Union City, California, two months after signing a termination agreement, ending a lease that had run through 2031.
Tenaya Therapeutics disclosed in an 8-K that on June 29, 2026, it signed a deal with Terreno Park Union City LLC to end its lease on a manufacturing building in Union City, California. The agreement covers roughly 94,046 rentable square feet at 33498 Central Avenue, Union City, California 94587.1
The site had housed the company's gene therapy manufacturing operations. Tenaya calls the space its Genetic Medicines Manufacturing Center, or GMMC Facility, and had already shut it down in 2025 as part of a cost-reduction effort.1 According to the filing, the company was able to close the facility because it has enough existing inventory of its drug candidates TN-201 and TN-401 on hand to support its current clinical trials.1
Under the original terms, the lease had been set to run until July 2031, but it will now end on August 31, 2026.1 Tenaya agreed to pay a price for the early exit: it will forfeit a $1,750,000 security deposit and pay a separate termination fee of about $294,200.1
The company said it is not walking away from its manufacturing expertise. Tenaya said it will keep its internal knowledge of manufacturing processes and testing methods, and intends to move its AAV production process to an outside contract manufacturer with global reach, positioning for possible later-stage trials or commercial production of TN-201 and TN-401 down the road.1
The filing was signed by Jennifer Drimmer Rokovich, the company's General Counsel and Secretary, and dated July 2, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.